(SARS-CoV-2) IgG/IgM Antibody Rapid Test Kit

Novel coronavirus (SARS-CoV-2) IgG/IgM Antibody Rapid Test Kit


This kit is suitable for in-vitro qualitative detection of antibodies against novel coronavirus pneumonia (COVID-19) in suspected/confirmed patients, serum/ whole blood samples (including peripheral blood).

Compared with nucleic acid detection, there is no false negative test result and the possibility of false positive test result is very low. The total coincidence rate is more than 97%. It can be used as a supplementary detection index for those with novel coronavirus nucleic acid test negative and suspected cases, or as a cooperative test of nucleic acid test in diagnosis of suspected cases, or as a confirmation in diagnosis and treatment.

Video link1:http://v.qq.com/x/page/q0937n1rc4p.html

Video link2:https://pan.baidu.com/s/1UhEk7Dtal45K4qSBTsXveg 


April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.